ClinicalTrials.gg
Active, not recruitingNCT03616587SERENA-1Updated Aug 18, 2026

Study of AZD9833 Alone or in Combination in Women With Advanced Breast Cancer.

A Phase 1 interventional study of AZD9833 and AZD9833 in ER+ HER2- Advanced Breast Cancer, sponsored by AstraZeneca. Active, not recruiting at 17 sites in 3 countries. Open to female participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2026-08-18.

Sponsored by AstraZeneca · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
396
Allocation
Randomized
Ages
18 Years to 130 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies testing AZD9833 in Breast Neoplasms — 6 open to participants now, 10 under way, 7 of them phase 3. AZD9833 · Breast Neoplasms.

Enrollment
5th of 17
396 · median 150
Started
2018
the only one that year
Phase 1
7 of 17
none open now
Registered
1st of 17
by date
Lead sponsor
15 of 17
AstraZeneca

Among the 17 studies testing AZD9833 in Breast Neoplasms, this one is the 5th largest by enrollment, is the only one that started in 2018, is one of 7 in phase 1, and was the 1st registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

6 of the 17 studies testing AZD9833 in Breast Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About AZD9833

AZD9833: first FDA approval 2026 (ETCAMAH), first EMA approval 2026. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years to 130 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing AZD9833 in Breast Neoplasms, or all of them as a file.
02

Study summary

A Phase 1 Dose Escalation and Expansion Study of AZD9833 Alone or in Combination in Women with ER Positive, HER2 Negative Advanced Breast Cancer (SERENA-1)

Read the detailed description

This is a multicentre dose escalation and expansion, first-in-human study designed to evaluate the safety and tolerability of AZD9833, alone (Parts A and B), or in combination with palbociclib (Parts C and D), or in combination with everolimus (Parts E and F), or in combination with abemaciclib (± anastrozole) (Parts G and H), or in combination with capivasertib (Parts I and J), or in combination with ribociclib (± anastrozole) (Parts K and L), or in combination with anastrozole (Parts M and N) in women with endocrine-resistant ER+ HER2- breast cancer that is not amenable to treatment with curative intent.

03

Conditions studied

  • ER+ HER2- Advanced Breast Cancer

Browse trials for

Keywords

  • Breast Cancer
  • Phase 1
  • Safety
  • Tolerability
  • Pharmacokinetics
  • ER Positive
  • HER2 Negative
  • Advanced Breast Cancer
  • Camizestrant
04

Who can participate

Ages eligible
18 Years to 130 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed written .
  2. >= 18 years
  3. Any menopausal status:

    1. Pre-menopausal women must have commenced treatment with an LHRH agonist at least 4 weeks prior to starting AZD9833 (± combination IMP(s)) and must be willing to continue to receive LHRH agonist therapy for the duration of the study
    2. defined according to standard criteria in the protocol.
  4. Histological or cytological confirmation of adenocarcinoma of the breast
  5. Documented positive oestrogen receptor status of primary or tumour tissue, according to the local laboratory parameters. negative.
  6. Metastatic disease or locoregionally recurrent disease which is or intolerant to existing therapy(ies) known to provide clinical benefit
  7. Metastatic or locoregionally recurrent disease and radiological or objective evidence of progression on or after the last systemic therapy prior to starting IMP
  8. Prior chemotherapy, endocrine therapy and other therapy as follows:

    1. No more than 2 for advanced disease
    2. Recurrence or progression on at least one line of endocrine therapy in the advanced/metastatic disease setting
    3. There is no limit on the number of lines of prior endocrine therapies
    4. Prior treatment with CDK4/6 inhibitors is permitted
  9. Women of must agree to use a highly effective measure, must not be breast feeding, and must have a negative pregnancy test prior to the start of dosing.
  10. At least one lesion (measurable and/or non-measurable, as per 1.1 that can be accurately assessed at baseline and is suitable for repeated assessment by CT, MRI, or plain X-ray; or clinical examination. Blastic-only lesions in bone are not considered assessable.
  11. / WHO performance status 0 to 1, with no deterioration over the previous 2 weeks and a minimum of 12 weeks Inclusion criteria for the paired tumour research:

    Inclusion criteria for the paired tumour biopsy research

  12. Disease suitable for paired baseline and on-study tumour biopsies
  13. Washout from prior fulvestrant: 6 months
  14. Washout from prior tamoxifen: 4 months
  15. Signed written informed consent for tumour biopsies

Exclusion criteria

Exclusion Criteria

  1. Intervention with any of the following

    1. Any cytotoxic chemotherapy, agents/other anti-cancer drugs for the treatment of advanced breast cancer from a previous treatment regimen or clinical study within 14 days of the first dose of IMP
    2. Concomitant medications or herbal supplements known to be strong inhibitors/inducers of cytochrome P450 (CYP) 3A4/5, sensitive CYP2B6 substrates, and drugs which are sensitive substrates of CYP2C9 and/or CYP2C19, and which have a narrow therapeutic index. In addition: Parts E and F will exclude the concomitant use of moderate and/or Pgp inhibitors; Parts G H, I, J, K and L will exclude the concomitant use of moderate CYP3A4/5 inhibitors and inducers; Parts I and J will exclude concomitant use of sensitive substrates of CYP3A4 and/or CYP2D6 with a narrow therapeutic index."
    3. Drugs known to prolong and known risk of Torsades de Pointes
    4. Radiotherapy with a limited field of radiation for palliation within 1 week of the first dose of IMP, except patients receiving radiotherapy to more than 30% of the bone marrow/a wide field of radiation within 4 weeks of the first dose of IMP
    5. Major surgical procedure/significant traumatic injury, as judged by the investigator, within 4 weeks of the first dose of IMP, or an anticipated need for major surgery and/or any surgery requiring general anaesthesia during the study.
  2. Any unresolved toxicities from prior therapy > Grade 1 at the time of starting IMP, with the exception of alopecia.
  3. Presence of life-threatening visceral disease, as judged by the investigator, uncontrolled CNS metastatic disease. Patients with spinal cord compression and/or may be enrolled if definitively treated (eg, surgery or radiotherapy) and stable off for at least 4 weeks prior to start of IMP
  4. Past medical history of ILD (Parts E, F, K and L only)
  5. Currently symptomatic radiotherapy-induced pneumonitis (Parts E, F, K and L only)
  6. Evidence of severe or uncontrolled systemic diseases, including uncontrolled hypertension and active bleeding diatheses, which in the investigator's opinion makes it undesirable for the patient to participate in the trial or which would jeopardise compliance with the protocol, or active infection including , , and (HIV)
  7. Any of the following cardiac criteria

    1. Mean resting QTcF >470 msec obtained from a triplicate (≥450 msec for Parts K and L)
    2. Any abnormalities in rhythm, conduction, or morphology of resting ECG (eg, complete left bundle branch block, second- and third-degree heart block), or clinically significant sinus pause. Patients with controlled atrial fibrillation can be enrolled c) Any factors that increase the risk of QTc prolongation or risk of arrhythmic events such as symptomatic heart failure, hypokalaemia, congenital long QT syndrome, immediate family history of long QT syndrome, or unexplained sudden death at \<40 years of age. Hypertrophic cardiomyopathy and clinically significant stenotic valve disease

    (d) \<50% and/or experience of any of the following procedures or conditions in the preceding 6 months: coronary artery bypass graft, angioplasty, vascular stent, myocardial infarction, unstable angina pectoris, congestive heart failure Grade ≥2, cerebrovascular accident, or .

    (e) Uncontrolled hypertension. Hypertensive patients may be eligible but blood pressure must be adequately controlled at baseline.

    (f) Uncontrolled hypotension - SBP \<90 mmHg and/or DBP \<50 mmHg for parts I \&J

  8. Inadequate bone marrow reserve/organ function as demonstrated by any of the following lab values

    1. ANC \<1.5 × 109/L
    2. count \<100 × 109/L
    3. \<90 g/L
    4. >2.5 ×
    5. AST >2.5 × ULN
    6. TBL >1.5 × ULN or >3 × ULN in the presence of documented Gilbert's Syndrome
    7. \<50 mL/min
  9. Clinically significant abnormalities of glucose metabolism, as defined by any of the following at screening (Parts I and J only):

    1. Patients with diabetes mellitus type I or diabetes mellitus type II requiring insulin treatment.
    2. ≥8.0% (63.9 mmol/mol).
Terms in these criteria, in plain language(32)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
396 participants (actual)

Study arms

  • Experimental
    AZD9833 monotherapy dose escalation

    Drug: AZD9833

  • Experimental
    AZD9833 monotherapy dose expansion

    Drug: AZD9833

  • Experimental
    AZD9833 with palbociclib dose escalation

    Drug: AZD9833 with palbociclib

  • Experimental
    AZD9833 with palbociclib dose expansion

    Drug: AZD9833 with palbociclib

  • Experimental
    AZD9833 with everolimus dose expansion

    Drug: AZD9833 with everolimus

  • Experimental
    AZD9833 with everolimus dose escalation

    Drug: AZD9833 with everolimus

  • Experimental
    AZD9833 with abemaciclib (± anastrozole) dose escalation

    Drug: AZD9833 with abemaciclib

  • Experimental
    AZD9833 with abemaciclib (± anastrozole)dose expansion

    Drug: AZD9833 with abemaciclib

  • Experimental
    AZD9833 with capivasertib dose escalation

    Drug: AZD9833 with capivasertib

  • Experimental
    AZD9833 with capivasertib dose expansion

    Drug: AZD9833 with capivasertib

  • Experimental
    AZD9833 with ribociclib (± anastrozole) dose escalation

    Drug: AZD9833 with ribociclib

  • Experimental
    AZD9833 with ribociclib (± anastrozole) dose expansion

    Drug: AZD9833 with ribociclib

  • Experimental
    AZD9833 with anastrozole dose escalation

    Drug: AZD9833 with anastrozole

  • Experimental
    AZD9833 with anastrozole dose expansion

    Drug: AZD9833 with anastrozole

Interventions

  • Part A: AZD9833 monotherapy dose escalation.

  • Part B: AZD9833 monotherapy expansion.

  • DrugAZD9833 with palbociclib

    Drug pages: AZD9833 · Palbociclib

    Part C: AZD9833 in combination with palbociclib dose escalation

  • DrugAZD9833 with palbociclib

    Drug pages: AZD9833 · Palbociclib

    Part D: AZD9833 in combination with palbociclib expansion

  • DrugAZD9833 with everolimus

    Drug pages: AZD9833 · Everolimus

    Part E: AZD9833 in combination with everolimus dose escalation

  • DrugAZD9833 with everolimus

    Drug pages: AZD9833 · Everolimus

    Part F: AZD9833 in combination with everolimus dose expansion

  • DrugAZD9833 with abemaciclib

    Drug pages: AZD9833 · Abemaciclib

    Part G: AZD9833 in combination with abemaciclib (± anastrozole) dose escalation

  • DrugAZD9833 with abemaciclib

    Drug pages: AZD9833 · Abemaciclib

    Part H: AZD9833 in combination with abemaciclib (± anastrozole) dose expansion

  • DrugAZD9833 with capivasertib

    Drug pages: AZD9833 · Capivasertib

    Part I: AZD9833 in combination with capivasertib dose escalation

  • DrugAZD9833 with capivasertib

    Drug pages: AZD9833 · Capivasertib

    Part J: AZD9833 in combination with capivasertib dose expansion

  • DrugAZD9833 with ribociclib

    Drug pages: AZD9833 · Ribociclib

    Part K: AZD9833 in combination with ribociclib (± anastrozole) dose escalation

  • DrugAZD9833 with ribociclib

    Drug pages: AZD9833 · Ribociclib

    Part L: AZD9833 in combination with ribociclib (± anastrozole) dose expansion

  • DrugAZD9833 with anastrozole

    Drug pages: AZD9833 · Anastrozole

    Part M: AZD9833 in combination with anastrozole dose escalation

  • DrugAZD9833 with anastrozole

    Drug pages: AZD9833 · Anastrozole

    Part N: AZD9833 in combination with anastrozole dose expansion

06

What researchers measure

Primary outcomes

  1. The number of subjects with dose-limiting toxicity, as defined in the protocol.

    Dose-limiting toxicity as described in the protocol that is not related to disease progression, intercurrent illness or concomitant medications and that, despite optimal therapeutic intervention, meets protocol-defined criteria.

    Time frame: Minimum observation period 28 days on treatment.

  2. The number of subjects with treatment-related adverse events as assessed by CTCAE v4.03.

    Data will include clinical observations, ECG parameters, clinical chemistry and haematology and vital signs assessed as the number of subjects with treatment-related adverse events assessed by CTCAE v4.03.

    Time frame: Minimum observation period 28 days on treatment, and will continue until the subject is off the study (approximately 1 year).

Secondary outcomes

  1. Objective Response Rate

    Antitumour activity by evaluation of tumour response assessments using Response Evaluation Criteria in Solid Tumours (RECIST 1.1)

    Time frame: Weeks 8, 16 and 24 and then every 12 weeks (weeks 36, 48 and 60) until the end of the study (approximately 1 year).

  2. Duration of Response

    Antitumour activity by evaluation of tumour response assessments using Response Evaluation Criteria in Solid Tumours (RECIST 1.1)

    Time frame: Weeks 8, 16 and 24 and then every 12 weeks (weeks 36, 48 and 60) until the end of the study (approximately 1 year).

  3. Clinical benefit rate at 24 weeks

    Antitumour activity by evaluation of tumour response assessments using Response Evaluation Criteria in Solid Tumours (RECIST 1.1)

    Time frame: Up to 24 weeks

  4. Percentage Change in Tumour Size

    Antitumour activity by evaluation of tumour response assessments using Response Evaluation Criteria in Solid Tumours (RECIST 1.1)

    Time frame: Weeks 8, 16 and 24 and then every 12 weeks (weeks 36, 48 and 60) until the end of the study (approximately 1 year).

  5. Progression Free Survival

    Antitumour activity by evaluation of tumour response assessments using Response Evaluation Criteria in Solid Tumours (RECIST 1.1)

    Time frame: Weeks 8, 16 and 24 and then every 12 weeks (weeks 36, 48 and 60) until the end of the study (approximately 1 year).

  6. Maximum Observed Plasma Concentration (Cmax) of AZD9833 alone or in combination with Palbociclib, Everolimus, Abemaciclib, Capivasertib, Ribociclib or Anastrozole

    Blood samples will be collected to assess plasma concentrations of AZD9833 alone or in combination with Palbociclib, Everolimus, Abemaciclib, Capivasertib, Ribociclib or Anastrozole at a series of timepoints to derive Cmax

    Time frame: At predefined intervals throughout the AZD9833 treatment period (approximately 16 weeks )

  7. Time to observed Cmax (Tmax) for AZD9833 alone or in combination with Palbociclib, Everolimus, Abemaciclib, Capivasertib, Ribociclib or Anastrozole

    Blood samples will be collected to assess plasma concentrations of AZD9833 alone or in combination with Palbociclib, Everolimus, Abemaciclib, Capivasertib, Ribociclib or Anastrozole at a series of timepoints to derive Tmax

    Time frame: At predefined intervals throughout the AZD9833 treatment period (approximately 16 weeks )

  8. Area under the plasma concentration-time curve (AUC) for AZD9833 alone or in combination with Palbociclib, Everolimus, Abemaciclib, Capivasertib, Ribociclib or Anastrozole

    Blood samples will be collected to assess plasma concentrations of AZD9833 alone or in combination with Palbociclib, Everolimus, Abemaciclib, Capivasertib, Ribociclib or Anastrozole at a series of timepoints to derive AUC

    Time frame: At predefined intervals throughout the AZD9833 treatment period (approximately 16 weeks )

  9. Renal clearance (CLR) for AZD9833

    Urine samples will be collected to assess urine concentrations of AZD9833 at a series of timepoints to derive renal clearance

    Time frame: At predefined intervals throughout the AZD9833 treatment period (approximately 16 weeks )

  10. Assessment of biomarker changes

    Tumour samples will be collected to assess biomarker changes of estrogen receptor (ER), progesterone receptor (PgR) and Ki67 protein at a series of timepoints to derive AZD9833 activity in tumour cells.

    Time frame: At pre-defined time intervals throughout the AZD9833 treatment period and at discontinuation. (approximately 1 year)

07

Study locations

17 sites
  • Research Site
    Aurora, Colorado 80045, United States
  • Research Site
    Sarasota, Florida 34232, United States
  • Research Site
    Philadelphia, Pennsylvania 19111, United States
  • Research Site
    Nashville, Tennessee 37203, United States
  • Research Site
    Salt Lake City, Utah 84112, United States
  • Research Site
    Barcelona, 08035, Spain
  • Research Site
    Barcelona, 8036, Spain
  • Research Site
    Madrid, 28041, Spain
  • Research Site
    Madrid, 28050, Spain
  • Research Site
    Seville, 41013, Spain
  • Research Site
    Valencia, 46010, Spain
  • Research Site
    Cambridge, CB2 0QQ, United Kingdom
  • Research Site
    Leeds, LS9 7TF, United Kingdom
  • Research Site
    London, SW2 6JJ, United Kingdom
  • Research Site
    Manchester, M20 4GJ, United Kingdom
  • Research Site
    Sutton, SM1 2DL, United Kingdom
  • Research Site
    Sutton, SM2 5PT, United Kingdom
08

References and documents

Related links

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2018 to primary completion in Sep 2024, 71 months.

Of 389 industry-sponsored phase 1 interventional studies under Breast Neoplasms, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 56. This study's 71 months is above that.

Counting every sponsor, half of 761 studies reached it within 44 months; a quarter within 25 and three quarters within 65.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 6, 2018
First posted
Aug 6, 2018
StartActual
Oct 11, 2018
Primary completionActual
Sep 16, 2024
CompletionEst.
Jun 24, 2027
Last update
Aug 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03616587
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Aug 6, 2018
Start date
Oct 11, 2018
Primary completion
Sep 16, 2024
Completion
Jun 24, 2027 (estimated)
Last update
Aug 18, 2026

Study contacts

Richard Baird, MD PhD FRCP
principal investigator · Breast Cancer Research Unit, University of Cambridge
Justin Lindemann, MBChB MBA
study director · AstraZeneca

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: AZD9833 · Palbociclib · Everolimus · Abemaciclib · Capivasertib · Ribociclib · Anastrozole

Start the discussion